the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris
NCT ID: NCT00419848
Last Updated: 2008-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
100 participants
INTERVENTIONAL
2006-08-31
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Efficacy of Azithromycin and Levamisole Versus of Azithromycin in in the Treatment of Acne
NCT01348321
The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne
NCT00388778
Anti-microbial Role of Non-antibiotic Agents Against Cutibacterium Acnes in Patients With Acne Vulgaris
NCT06179056
Efficacy And Safety Of Azithromycin SR Compared With Minocycline In Acne
NCT00392223
Subantimicrobial Doxycycline in Acne
NCT05399290
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Azithromycin
Azithromycin: Cap 250 mg- 500 mg single dose/daily - 3 times per week
2
Doxycycline
Cap 100mg- 100mg/daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doxycycline
Cap 100mg- 100mg/daily
Azithromycin
Azithromycin: Cap 250 mg- 500 mg single dose/daily - 3 times per week
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate facial Acne(At least 10 inflammatory lesions with maximum 3 nodules and pseudocysts
Exclusion Criteria
* Breast Feeding
* Acne Fulminant
* Acne conglobate
* Isotretinoin therapy within past 6 months
* topical treatment in last 2 weeks
* use of systemic antibiotic in the last month
* Hyperandrogenism symptoms
* Menstrual irregularity
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shahid Beheshti University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shaheed Beheshti Medical unversity
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Parviz Toossi, M.D.
Role: STUDY_CHAIR
Skin Research Center
Hamideh Moravvej, M.D.
Role: PRINCIPAL_INVESTIGATOR
Skin Research Center
Akbar Mousazadeh halim, M.D.
Role: PRINCIPAL_INVESTIGATOR
Skin Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shaheed Beheshti Medical University, Skin research center
Tehran, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
src-hmj-1385
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.